title: Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice.
abstract: The objective of the present study was to compare the activities of regimens containing linezolid (LZD) with those not containing LZD against Mycobacterium tuberculosis infection in mice. The three regimens excluding LZD selected in this study are often used in practice against multidrug-resistant tuberculosis (MDR-TB). When LZD was added to these MDR-TB regimens, the combinations were significantly more active after 2 months of therapy with regard to lung CFU reductions. The activity of LZD-containing regimens was greater than the World Health Organization's standard first-line regimen of rifampicin+isoniazid+pyrazinamide. In particular, when LZD was included in the combination levofloxacin+amikacin+para-aminosalicylic acid+pyrazinamide+clofazimine, culture negativity of the lungs was reached after 2 months of treatment in every case. In addition, the serum levels of interleukin-10 and interferon-γ of mice were determined and were found not to be surrogate markers of bacterial clearance.
authors.affiliation: Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. Electronic address: zhaoweijie415@163.com.
authors.forename: Weijie
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Pharmacy of Beijing Chest Hospital affiliated to The Capital Medical University, Beijing, China.
authors.forename: Zhenyong
authors.initials: Z
authors.lastname: Guo
authors.affiliation: Pharmacy of Beijing Chest Hospital affiliated to The Capital Medical University, Beijing, China.
authors.forename: Meiqin
authors.initials: M
authors.lastname: Zheng
authors.affiliation: Pharmacy of Beijing Chest Hospital affiliated to The Capital Medical University, Beijing, China.
authors.forename: Jinfu
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.affiliation: Pharmacy of Beijing Chest Hospital affiliated to The Capital Medical University, Beijing, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Li
authors.affiliation: Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Fu
authors.affiliation: Pharmacy of Beijing Chest Hospital affiliated to The Capital Medical University, Beijing, China.
authors.forename: Shuo
authors.initials: S
authors.lastname: Liu
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D058491:Bacterial Load; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D000069349:Linezolid; D008168:Lung / Q000382:microbiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D023303:Oxazolidinones / Q000627:therapeutic use*; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000081:Acetamides; D000995:Antitubercular Agents; D023303:Oxazolidinones; D016753:Interleukin-10; D007371:Interferon-gamma; D000069349:Linezolid
keywords: Activity; Combination regimen; Cytokine; Extensively drug-resistant tuberculosis; Linezolid; Multidrug-resistant tuberculosis